Ross DM - Search Results

1

Targeting Acute Myeloid Leukemia Using Sphingosine Kinase 1 Inhibitor-Loaded Liposomes.

Nguyen TM, Jambhrunkar M, Wong SS, Ross DM, Joyce P, Finnie JW, Manavis J, Bremmell K, Pitman MR, Prestidge CA. Nguyen TM, et al. Among authors: ross dm. Mol Pharm. 2023 Aug 7;20(8):3937-3946. doi: 10.1021/acs.molpharmaceut.3c00078. Epub 2023 Jul 18. Mol Pharm. 2023. PMID: 37463151

2

Masked polycythaemia vera is genetically intermediate between JAK2V617F mutated essential thrombocythaemia and overt polycythaemia vera.

Tiong IS, Casolari DA, Nguyen T, Van Velzen MJ, Ambler K, D'Andrea RJ, Ross DM. Tiong IS, et al. Among authors: ross dm. Blood Cancer J. 2016 Aug 19;6(8):e459. doi: 10.1038/bcj.2016.70. Blood Cancer J. 2016. PMID: 27540717 Free PMC article. No abstract available.

3

Ceramide-induced integrated stress response overcomes Bcl-2 inhibitor resistance in acute myeloid leukemia.

Lewis AC, Pope VS, Tea MN, Li M, Nwosu GO, Nguyen TM, Wallington-Beddoe CT, Moretti PAB, Anderson D, Creek DJ, Costabile M, Ali SR, Thompson-Peach CAL, Dredge BK, Bert AG, Goodall GJ, Ekert PG, Brown AL, D'Andrea R, Robinson N, Pitman MR, Thomas D, Ross DM, Gliddon BL, Powell JA, Pitson SM. Lewis AC, et al. Among authors: ross dm. Blood. 2022 Jun 30;139(26):3737-3751. doi: 10.1182/blood.2021013277. Blood. 2022. PMID: 35443029 Free PMC article.

4

Combating Acute Myeloid Leukemia via Sphingosine Kinase 1 Inhibitor-Nanomedicine Combination Therapy with Cytarabine or Venetoclax.

Nguyen TM, Joyce P, Ross DM, Bremmell K, Jambhrunkar M, Wong SS, Prestidge CA. Nguyen TM, et al. Among authors: ross dm. Pharmaceutics. 2024 Jan 31;16(2):209. doi: 10.3390/pharmaceutics16020209. Pharmaceutics. 2024. PMID: 38399263 Free PMC article.

5

Vosaroxin is a novel topoisomerase-II inhibitor with efficacy in relapsed and refractory acute myeloid leukaemia.

Hotinski AK, Lewis ID, Ross DM. Hotinski AK, et al. Among authors: ross dm. Expert Opin Pharmacother. 2015 Jun;16(9):1395-402. doi: 10.1517/14656566.2015.1044437. Epub 2015 May 10. Expert Opin Pharmacother. 2015. PMID: 25958926 Review.

6

A novel, somatic, transforming mutation in the extracellular domain of Epidermal Growth Factor Receptor identified in myeloproliferative neoplasm.

Casolari DA, Nguyen T, Butcher CM, Iarossi DG, Hahn CN, Bray SC, Neufing P, Parker WT, Feng J, Maung KZY, Wee A, Vidovic L, Kok CH, Bardy PG, Branford S, Lewis ID, Lane SW, Scott HS, Ross DM, D'Andrea RJ. Casolari DA, et al. Among authors: ross dm. Sci Rep. 2017 May 26;7(1):2467. doi: 10.1038/s41598-017-02655-7. Sci Rep. 2017. PMID: 28550306 Free PMC article.

7

Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission.

Pagani IS, Dang P, Saunders VA, Grose R, Shanmuganathan N, Kok CH, Carne L, Rwodzi Z, Watts S, McLean J, Braley J, Altamura H, Yeung DT, Branford S, Yong ASM, White DL, Hughes TP, Ross DM. Pagani IS, et al. Among authors: ross dm. Leukemia. 2020 Apr;34(4):1052-1061. doi: 10.1038/s41375-019-0647-x. Epub 2019 Nov 25. Leukemia. 2020. PMID: 31768016

8

Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia.

Irani YD, Kok CH, Clarson J, Shanmuganathan N, Branford S, Yeung DT, Ross DM, Hughes TP, Yong ASM. Irani YD, et al. Among authors: ross dm. Blood Adv. 2023 Jun 13;7(11):2364-2374. doi: 10.1182/bloodadvances.2022008854. Blood Adv. 2023. PMID: 36622326 Free PMC article.

9

Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR.

Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Bartley PA, Slader C, Field C, Dang P, Filshie RJ, Mills AK, Grigg AP, Melo JV, Hughes TP. Ross DM, et al. Leukemia. 2010 Oct;24(10):1719-24. doi: 10.1038/leu.2010.185. Epub 2010 Sep 2. Leukemia. 2010. PMID: 20811403

10

Minimal residual disease and discontinuation of therapy in chronic myeloid leukemia: can we aim at a cure?

Melo JV, Ross DM. Melo JV, et al. Among authors: ross dm. Hematology Am Soc Hematol Educ Program. 2011;2011:136-42. doi: 10.1182/asheducation-2011.1.136. Hematology Am Soc Hematol Educ Program. 2011. PMID: 22160025 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

193 results

Search Page